title: Lipid Profile of Anti-Retroviral Treatment-Naïve HIV-Infected Patients in Jos, Nigeria.
abstract: BACKGROUND
  Human immunodeficiency virus (HIV) infection and its treatment are associated with lipid abnormalities. Data on lipid profile of treatment-naïve HIV-infected patients in Nigeria are limited, and available studies did not exclude the role of major host-related risk factors for dyslipidemia.
  
  
  OBJECTIVE
  We assessed the lipid profile of normotensive, non-diabetic, and non-obese treatment-naïve HIV-infected patients to identify their abnormalities in comparison with age- and sex-matched HIV-negative control.
  
  
  METHODS
  One hundred and six normotensive, non-diabetic, and non-obese HIV positive patients and 98 age-and sex-matched HIV-negative controls had lipid profile estimation in the fasting state. The CD4+ cell count of the HIV-infected patients was also quantified.
  
  
  RESULTS
  The median (IQR) triglyceride was significantly higher in HIV-positive patients than in the controls [1.75 (1.30-2.40) mmol/L vs. 1.55 (1.30-1.90) mmol/L, P = 0.01]. HIV-positive patients also had significantly lower mean total cholesterol, TC [4.18 (1.04) mmol/L vs. 4.64 (1.01) mmol/L, P = 0.001] and HDL-C [1.17 (0.35) mmol/L vs. 1.29 (0.43) mmol/L, P = 0.03]. The mean LDL-C [2.20 (0.87) mmol/L vs. 2.19 (0.75) mmol/L, P = 0.97] and TC/HDL-C ratio [3.95 (1.42) vs. 3.84 (1.14) mmol/L, P = 0.52] were similar between the HIV-positive patients and controls. The HIV-infected patients had a significantly higher proportion of subjects with low HDL-C [36.8% (39/106) vs. 23.5% (23/98), P = 0.04] and hypertriglyceridemia [31.1% (33/106) vs. 11.2% (11/98), P = 0.001] while the controls had significantly higher proportion of subjects with hypercholesterolemia [22.4% (22/98) vs. 10.4% (11/106), P = 0.02]. Lower HDL-C was associated with CD4+ cell count < 200 cells/μL (P = 0.02).
  
  
  CONCLUSIONS
  Lipid abnormalities are common in treatment-naïve HIV-infected patients even in the absence of major host-related risk factors for dyslipidemia. HIV-infected patients should, therefore, be routinely screened for lipid disorders before commencement of anti-retroviral therapy.
authors: Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria.
authors: Ca
authors: C
authors: Daniyam
authors: Mo
authors: M
authors: Iroezindu
keywords: Africa; Dyslipidemia; Human immunodeficiency virus; Lipid profile
references: Can J Cardiol. 1988 Jul;4 Suppl A:5A-10A
references: 3179802
references: AIDS. 1998 May 7;12(7):F51-8
references: 9619798
references: N Engl J Med. 1992 Jul 30;327(5):329-37
references: 1620172
references: Clin Infect Dis. 2003 Sep 1;37(5):613-27
references: 12942391
references: HIV Med. 2010 Jul 1;11(6):353-9
references: 20345886
references: Infection. 1999 Mar-Apr;27(2):77-81
references: 10219634
references: Eur Heart J. 1998 Oct;19 Suppl M:M8-14
references: 9821011
references: AIDS Res Hum Retroviruses. 2007 Nov;23(11):1338-47
references: 18184075
references: J Clin Endocrinol Metab. 1992 May;74(5):1045-52
references: 1373735
references: Am J Med. 1993 May;94(5):515-519
references: 7605397
references: JAMA. 2003 Jun 11;289(22):2978-82
references: 12799406
references: Afr Health Sci. 2010 Jun;10(2):144-9
references: 21326966
references: MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
references: 1361652
references: N Engl J Med. 1998 Mar 26;338(13):853-60
references: 9516219
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Antivir Ther. 2005;10(5):585-91
references: 16152752
references: Rev Med Brux. 2000 Feb;21(1):11-7
references: 10748683
references: World Health Organ Tech Rep Ser. 1994;841:1-53
references: 8184600